RLMD

Current Price Range

\~$7.17 – $7.30 ▲ Volatile

Previous Close

$7.17

Assessment Date

May 28, 2026

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system disorders. Its lead candidate, NDV-01, is a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC), advancing toward Phase 3. The company also has sepranolone in development for compulsive behaviors and Prader-Willi syndrome.

Swing Trade Scenarios & Risk Profiles

Scenario	Entry Point	Stop-Loss	Target(s)	Potential Return	R:R Ratio	Est. Prob.	Strategic Notes
Bullish Pullback Buy PRIMARY	$6.80 – $7.10 (Near-term support zone)	Below $6.20 – $6.40 (10–12% risk)	$9.00 (T1) $11.00–$12.00 (T2)	+25% to +65%+	1:2.0+	\~52–62%	High-reward biotech setup. Pipeline progress on NDV-01 (bladder cancer) and sepranolone supports upside potential.
Breakout Continuation AGGRESSIVE	Above $7.60 – $7.80 on volume	$6.90 – $7.10 zone	$9.50 (T1) $12+ (T2)	+20% to +60%+	1:2.5+	\~48–58%	Momentum continuation if it breaks recent resistance. Watch for clinical or regulatory catalysts.
Range-Bound Swing	$6.90 – $7.50	Below $6.30	$8.50 – $9.00	+15% to +25%	1:1.8	\~50–60%	Lower risk consolidation while awaiting pipeline updates.

Risk Management Directives

• Limit risk to 1% of total portfolio equity per trade.
• Prefer pullback entries with volume confirmation and bullish reversal patterns.
• Take partial profits at Target 1 and trail the remainder.
• Move stop to breakeven after Target 1 is reached.
• High volatility clinical-stage biotech — size positions conservatively and monitor clinical trial news and FDA updates closely.

Strategic Conclusion: RLMD is a speculative biotech play with meaningful upside potential tied to its advancing pipeline in oncology (NDV-01 for bladder cancer) and CNS disorders. While typical biotech volatility and binary risk apply, recent price action and analyst interest make pullbacks attractive swing opportunities for higher-risk-tolerant traders.

Required Financial Disclaimer

This report is for educational purposes only. Not financial advice. Trading involves substantial risk of loss. Always conduct your own research and due diligence.